Topotecan (DrugBank: Topotecan)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 25 | Progressive multifocal leukoencephalopathy | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00002395 (ClinicalTrials.gov) | June 1996 | 2/11/1999 | Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML) | An Open, Comparative Phase II Study of Immediate Versus Delayed Treatment With Topotecan HCl Given as a Continuous 21-Day Infusion Every 28 Days to Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy | HIV Infections;Leukoencephalopathy, Progressive Multifocal | Drug: Topotecan | SmithKline Beecham | NULL | Completed | 18 Years | N/A | Both | 54 | Phase 2 | United States |